| 摘要 |
The invention relates to medicine, namely to immunotherapy. Summary of the invention consists in the fact that the monoclonal immunostimulating antibody or the antibody fragment, which binding an antigen, being bound up with the B lymphoblastoid cells, induces the proliferation and activation of the peripheral blood lymphocytes, ensures an antitumorous effect. The proposed antibody is obtained by immunization of the animal with an immunogen from the group consisting of B lymphoblastoid cells, lysed B lymphoblastoid cells and membranous preparations thereof, the subsequent development of the immune reaction to the immunized animals, extraction of B lymphocytes, growing, immortalization and selection of cell lines, secreting the proposed antibody. It is also claimed the Hybridome cell line deposited in the CNCM under No. I-1397. It is proposed a method of disease treatment, including the administration of an efficient amount of the proposed monoclonal immunostimulating antibody. It is claimed a pharmaceutical composition, including in the capacity of an active ingredient the proposed monoclonal immunostimulating antibody. Moreover, the pharmaceutical composition can additionally comprise an agent increasing the activity of cytotoxic lymphocytes. The result consists in the proliferation and activation of lymphocytes, ensuring the antitumorous effect. Claims: 18 Fig.: 10 |
